AstraZeneca to Work with Ionis on Eplontersen Drug
December 07 2021 - 3:09AM
Dow Jones News
By Joe Hoppe
AstraZeneca PLC said Tuesday that it will collaborate with Ionis
Pharmaceuticals Inc., to jointly develop and commercialize the
Californian biotechnology company's antisense drug Eplontersen.
The companies will jointly develop and commercialize the drug in
the U.S., while AstraZeneca will develop and commercialize
Eplontersen in the rest of the world, except for Latin America, it
said.
The pharmaceutical company will pay Ionis $200 million up front
and additional conditional payments of up to $485 million after
regulatory approvals. It will also pay up to $2.9 billion of
sales-related milestones, and royalties in the range of a low
double-digit to a mid-twenties percentage, depending on the
region.
Eplontersen, which is currently in phase 3 clinical trials,
treats amyloid transthyretin cardiomyopathy, or ATTR-CM--a
systemic, progressive and fatal condition that leads to progressive
heart failure and death within four years of diagnosis. It also
treats amyloid transthyretin polyneuropathy, or ATTR-PN, a disease
causing peripheral nerve damage with motor disability within five
years of diagnosis, and is generally fatal within a decade if
untreated.
Hereditary ATTR-PN treatment is likely to be the first
regulatory approval for Eplontersen, with the potential to file a
new drug application with the U.S. Food and Drug Administration by
the end of 2022.
Write to Joe Hoppe at joseph.hoppe@wsj.com
(END) Dow Jones Newswires
December 07, 2021 02:54 ET (07:54 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
AstraZeneca (NASDAQ:AZN)
Historical Stock Chart
From Aug 2024 to Sep 2024
AstraZeneca (NASDAQ:AZN)
Historical Stock Chart
From Sep 2023 to Sep 2024